Incyte gibt Langzeitdaten nach 24 Wochen aus der Phase-3-Studie TRuE-AD4 zur Opzelura® (Ruxolitinib)-Creme bei Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt

Key Takeaway: Incyte has released long-term data from the Phase 3 TRuE-AD4 study regarding Opzelura® (Ruxolitinib) cream for adults with moderate atopic dermatitis. The study's findings are expected to provide insights into the treatment's efficacy and safety over a 24-week period. Further details on the results and implications for patients will be crucial for stakeholders.